As­traZeneca, Mer­ck notch an­oth­er ma­jor Lyn­parza tri­al win — this time in pan­cre­at­ic can­cer

As­traZeneca and Mer­ck’s PARP in­hibitor Lyn­parza has chalked up an­oth­er land­mark win.

Months af­ter se­cur­ing a light­ning fast ap­proval for the use of the drug in front­line ovar­i­an can­cer — widen­ing their lead over the clus­ter of oth­er PARPs in­clud­ing Tesaro’s (now GSK’s) Ze­ju­la and Clo­vis’ Rubra­ca — Lyn­parza has shown promise in help­ing pa­tients with BR­CA-mu­tat­ed metasta­t­ic pan­cre­at­ic can­cer live longer with­out their can­cer pro­gress­ing in a late-stage study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER